Kynos Therapeutics has emerged from 'stealth mode' with £9m to finance its lead KMO inhibitor programme through Phase 1 clinical trials.
The spin-out from the University of Edinburgh is based on more than a decade of research into kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology and its inhibitors.
Its technology was co-developed during a multi-year collaborative programme between the university-based founders and GSK. The collaboration concluded in 2019, with data, rights and intellectual property transferred to the university - although GSK is eligible for a royalty should a medicine be registered.
